Mylan launches first bioequivalent alternative to Advair Diskus in Canada

10 Mar 2020

Appropriate asthma and COPD patients provided with a "more affordable alternative to appropriate".

Mylan Pharmaceuticals has launched Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) — the first available bioequivalent alternative to GSK's Advair Diskus in Canada.

Mylan launches first bioequivalent alternative to Advair Diskus in Canada
Myland Pharmaceuticals' Wixela Inhub.

Advair Diskus is a leading treatment for asthma and chronic obstructive pulmonary disease (COPD) management. According to IQVIA, it had Canadian sales of $113.9 million for the 12 months ending 31 December 2019.

Wixela Inhub is a dry powder inhaler and is the result of $700 million investment worldwide, including an extensive research and development program. It was approved by Health Canada in January for the twice-daily maintenance treatment of asthma in patients age 4 and older not adequately controlled on long-term asthma control medications or whose disease warrants initiation of treatment with both inhaled corticosteroids and long-acting beta2-agonists; or maintenance treatment of COPD.

For asthma patients, Wixela Inhub is available in 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths, whereas for COPD patients, it is available in 250 mcg/50 mcg and 500 mcg/50 mcg strengths.

With today's launch in Canada, Mylan Canada Country Manager David Simpson commented: "We are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients."

Read More

Related news

UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

3 Apr 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

The Chinese pharmaceutical CDMO sector is set for rapid expansion, thanks to major amendments to the country's Drug Administration Law that make outsourcing manufacturing easier

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials on Tuesd...

Read more 
New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
Cambrex names Troy Player as head of early stage development and testing

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more 
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

31 Mar 2020

The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.

Read more 
EMA to only issue electronic medicines certificates during COVID-19 pandemic

EMA to only issue electronic medicines certificates during COVID-19 pandemic

30 Mar 2020

The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...

Read more 
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

30 Mar 2020

Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.

Read more 
New device offers a convenient way to monitor compressed air for viable particles

New device offers a convenient way to monitor compressed air for viable particles

30 Mar 2020

Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.

Read more